Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial
August 20 2024 - 8:00AM
Business Wire
Mr. Wild brings over 20 years of experience
building profitable commercial organizations at leading healthcare
brands
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, today announced the appointment of Adrian Wild as
SVP, International Commercial. Effective August 13, 2024, Mr. Wild
assumed the role and will lead the Company’s international
commercial sales and operations functions.
"We are thrilled to welcome Adrian to Allurion and add his
expertise to our leadership team as we advance the company toward
profitability," said Dr. Shantanu Gaur, Allurion’s Founder and CEO.
"Adrian joins us at an extremely important time – where the obesity
market is expanding by the day and presenting Allurion new
opportunities for growth. Adrian’s expertise in building
sustainable commercial organizations will be vital to our long-term
success plans.”
“This is a great time to join Allurion as it enters a new stage
of growth and development in an ever-expanding market,” said Mr.
Wild. “I look forward to working with the talented team at Allurion
to capitalize on this opportunity and take the company’s commercial
organization to new heights.” Mr. Wild brings a wealth of
experience in driving business growth and operational excellence
across global markets. For over a decade, he held leadership roles
at Align Technology where he contributed to establishing a new
standard of care and oversaw Align’s expansion in Europe to become
an international market leader. Immediately prior to joining
Allurion, he served as SVP and Head of Western Europe at Straumann
Group, a global leader in dental implants and orthodontic
solutions, where he helped Straumann achieve significant growth
through strategic marketing and operational initiatives. Prior to
Straumann, Mr. Wild was VP, Commercial Excellence Global at
M�lnlycke Health Care, a global medical technology company
specializing in wound care and surgical solutions where he helped
improve commercial effectiveness across more than 100
countries.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight loss platform that features the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less™
intragastric balloon for weight loss, and offers access to the
Allurion Virtual Care Suite, including the Allurion Mobile App for
consumers, Allurion Insights for health care providers featuring
the Coach Iris AI Platform, and the Allurion Connected Scale. The
Allurion Virtual Care Suite is also available to providers
separately from the Allurion Program to help customize, monitor and
manage weight loss therapy for patients regardless of their
treatment plan: gastric balloon, surgical, medical or nutritional.
The Allurion Gastric Balloon is an investigational device in the
United States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com.
Allurion is a trademark of Allurion Technologies, Inc. in the
United States and countries around the world.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240820207152/en/
Investors Mike Cavanaugh, Investor Relations ICR
Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com
Global Media Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Aug 2023 to Aug 2024